Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pediatrix Medical Group, Inc.MD · Entity 4451 | Chief Operating Officer | December 01, 2019 | December 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pediatrix Medical Group, Inc.
Report date December 01, 2019 · Filed December 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,032 |
Reported balance
After 2019-12-01 transaction · row 1
1 source rowRow 1 · 2019-12-01 · Tax withholding · Disposed 10,625 · Balance 123,032 F1: Represents 10,625 shares withheld for payment of taxes upon vesting of shares previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 10,625 shares withheld for payment of taxes upon vesting of shares previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2019 Filed Dec 3, 2019 21:50 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 10,625 | $26.12 | $277,525.00 |
DisclosureSEC source: 0001209191-19-058733 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,032 F1 · kind: Represents 10,625 shares withheld for payment of taxes upon vesting of shares previously reported. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:53 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 3,307 | $24.66 | $81,550.62 |
DisclosureSEC source: 0001209191-19-034363 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,657 F1 · kind: Represents 3,307 shares withheld for payment of taxes upon vesting of shares previously reported. Read SEC document |
| March 01, 2019 Filed Mar 1, 2019 22:12 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 6,452 | $32.90 | $212,262.41 |
DisclosureSEC source: 0001209191-19-015105 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,964 F1 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in twenty-seven (27) separate transactions with prices ranging from $32.73 to $33.26 for an average weighted sales price of $32.8987. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this section. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:32 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 56,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010176 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,416 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 14,143 additional shares based on the achievement of certain performance-based criteria for the twelve months ended December 31, 2019. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three equal installments on March 1, 2020, March 1, 2021 and March 1, 2022. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:58 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060911 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Pres. Mednax Natl Med Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,845 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended. Shares will vest in three installments on December 1, 2019, December 1, 2020 and December 1, 2021. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 21:32 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 11,607 | $45.15 | $524,095.51 |
DisclosureSEC source: 0001209191-18-034783 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Pres. Mednax Natl Med Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,845 F1 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in seventy-seven (77) separate transactions with prices ranging from $44.50 to $45.95 for an average weighted sales price of $45.1534. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this section. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 19,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015777 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Pres. Mednax Natl Med Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,452 F1 · shares: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 4,838 additional shares based on the achievement of certain performance-based criteria for the twelve months ended December 31, 2018. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will vest in three equal installments on March 1, 2019, March 1, 2020 and March 1, 2021. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:35 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantRestricted Shares Units · Derivative | 14,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-064791 · doc4.xml · derivative · entry 1 Clark David A. · CIK 0001443082 · Pres. Mednax Natl Med Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,741 Underlying: Common Stock · 14,741 shares Expires 2020-05-15 F1 · security: Restricted Shares Units, or Deferred Stock, granted under the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended. F2 · derivative.exercise_price: Each Restricted Share Unit represents the equivalent of one share of Issuer's Common Stock. F3 · derivative.exercise_date: Restricted Shares Units become payable in shares of Issuer's Common Stock and will vest after satisfaction of certain performance-based and time-based criteria. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:39 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 10,202 | $54.99 | $561,040.63 |
DisclosureSEC source: 0001209191-17-037298 · doc4.xml · nonDerivative · entry 2 Clark David A. · CIK 0001443082 · Pres. Mednax Natl Med Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,100 F2 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in fifty-three (53) separate transactions with prices ranging from $54.16 to $55.39 for an average weighted sales price of $54.9932. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:39 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 15,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037298 · doc4.xml · nonDerivative · entry 1 Clark David A. · CIK 0001443082 · Pres. Mednax Natl Med Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,302 F1 · shares: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The vesting of the restricted shares is subject to performance based criteria but will not vest any earlier than in three equal installments on June 1, 2018, June 1, 2019 and June 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.